Early Communications About Ongoing Safety Reviews

• Early Communication about an Ongoing Safety Review of Meridia (sibutramine hydrochloride) (11/20/2009)
• Early Communication about an Ongoing Safety Review of Deferasirox (marketed as Exjade) (9/25/2009)
• Early Communication about an Ongoing Safety Review of Orlistat (marketed as Alli and Xenical) (8/24/2009)

• Early Communication about an Ongoing Safety Review of Omalizumab (marketed as Xolair) (7/16/2009)

• Early Communication About Safety of Lantus (insulin glargine) (7/1/2009)
• Early Communication about an Ongoing Safety Review Xigris (Drotrecogin alfa [activated]) (2/4/2009)
• Early Communication about an Ongoing Safety Review of clopidogrel bisulfate (marketed as Plavix) (1/26/2009)
• Early Communication about an Ongoing Safety Review of Epoetin alfa (9/26/2008)
• Follow-up to the January 25, 2008 Early Communication about an Ongoing Data Review for Ezetimibe/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and Simvastatin (marketed as Zocor) 
• Early Communication About an Ongoing Safety Review of Ezetimibe/Simvastatin (marketed as Vytorin), Simvastatin (marketed as Zocor) and Ezetimibe (marketed as Zetia) - FDA Investigates a Report from the SEAS Trial (8/21/2008)
• Early Communication about an Ongoing Safety Review of Ziagen (Abacavir) and Videx (Didanosine) (7/24/2008)
• Early Communication about an Ongoing Safety Review of Aprotinin Injection (marketed as Trasylol) 
• Early Communication of an Ongoing Safety Review of Bisphosphonates: Alendronate (Fosamax, Fosamax Plus D), Etidronate (Didronel), Ibandronate (Boniva), Pamidronate (Aredia), Risedronate (Actonel, Actonel W/Calcium), Tiludronate (Skelid), and Zoledronic acid (Reclast, Zometa) 
• Update of Safety Review Follow-up to the October 1, 2007 Early Communication about the Ongoing Safety Review of Bisphosphonates

• Follow-up to the February 8, 2008, Early Communication about an Ongoing Safety Review of Botox and Botox Cosmetic

  (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B)

• Early Communication about an Ongoing Safety Review of Botox and Botox Cosmetic (Botulinum toxin Type A) and Myobloc (Botulinum toxin Type B) 
• Early Communication About an Ongoing Safety Review of Cefepime (marketed as Maxipime)
• Early Communication about an Ongoing Data Review for Ezetimibe/Simvastatin (marketed as Vytorin), Ezetimibe (marketed as Zetia), and Simvastatin (marketed as Zocor)
• Early Communication About an Ongoing Safety Review of Montelukast (Singulair)
• Early Communication About an Ongoing Safety Review of Omeprazole (Prilosec) and Esomeprazole (Nexium)
• Early Communication about an Ongoing Safety Review of Tiotropium (marketed as Spiriva HandiHaler)
• Early Communication About an Ongoing Safety Review of Tumor Necrosis Factor (TNF) Blockers (marketed as Remicade, Enbrel, Humira, and Cimzia)
• Early Communication About an Ongoing Safety Review of Varenicline (marketed as Chantix)